| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Cefadroxil targets penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. By binding to and inactivating PBPs, it inhibits bacterial cell wall synthesis, leading to bacterial cell death. The compound is an orally active cephalosporin antibiotic. It is absorbed in the small intestine via the intestinal peptide transporter PepT1.
|
|---|---|
| ln Vitro |
In vitro, Cefadroxil has bactericidal activity against a broad spectrum of Gram-positive and Gram-negative bacteria. It inhibits bacterial cell wall synthesis. Its antibacterial spectrum and potency have been characterized in various bacterial strains. The compound's activity against Streptococcus pyogenes has been demonstrated.
|
| ln Vivo |
In vivo, Cefadroxil is used for the treatment of pharyngitis, tonsillitis, and other mild to moderate susceptible infections caused by Gram-positive and Gram-negative bacteria. It is an orally active cephalosporin antibiotic absorbed via the intestinal peptide transporter PepT1. It is effective in eradicating S. pyogenes from the nasopharynx.
|
| Enzyme Assay |
In cell-free biochemical assays, Cefadroxil is evaluated for its binding affinity to penicillin-binding proteins and its antibacterial activity. The compound's purity and molecular weight are characterized using analytical techniques. Its ability to inhibit bacterial cell wall synthesis is assessed in biochemical assays.
|
| Cell Assay |
Cellular assays for Cefadroxil involve evaluating its antibacterial activity against various bacterial strains. Minimum inhibitory concentration (MIC) assays are performed to determine the compound's potency against Gram-positive and Gram-negative bacteria. Its effects on bacterial cell wall synthesis and viability are studied.
|
| Animal Protocol |
Animal models for Cefadroxil include models of bacterial infection. The compound is typically administered orally. Studies have examined its efficacy in treating infections caused by susceptible bacteria. Its pharmacokinetic properties and tissue distribution have been characterized.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cefadroxil show that the compound has a molecular weight of 363.39 g/mol. The CAS number is 66592-87-8. The compound is orally active and absorbed via the intestinal peptide transporter PepT1. Comparative human oral clinical pharmacology studies have been conducted. Standard handling procedures for cephalosporin antibiotics apply.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Cefadroxil is typical of cephalosporin antibiotics. As an antibacterial agent, it is generally well-tolerated at therapeutic doses. Standard safety precautions for handling pharmaceutical compounds apply. The compound is for research use only and not for human use except in approved clinical applications.
|
| Additional Infomation |
Cefadroxil monohydrate is the monohydrate of the cephalosporin cefalexin. It contains one cefalexin molecule. Cefadroxil is a semi-synthetic β-lactam first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of the bacterial cell wall. PBP is an enzyme involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during bacterial growth and division. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This leads to weakening of the bacterial cell wall and ultimately cell lysis. This is a long-acting, broad-spectrum, water-soluble cefalexin derivative.
Cefadroxil is a first-generation cephalosporin antibiotic with bactericidal activity against Gram-positive and Gram-negative bacteria. It is used for the treatment of pharyngitis, tonsillitis, and other susceptible infections. The CAS number is 66592-87-8. |
| Molecular Formula |
C16H19N3O6S
|
|---|---|
| Molecular Weight |
381.403
|
| Exact Mass |
381.099
|
| CAS # |
66592-87-8
|
| Related CAS # |
Cefadroxil;50370-12-2
|
| PubChem CID |
47964
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
789.9ºC at 760 mmHg
|
| Melting Point |
197ºC
|
| Flash Point |
431.5ºC
|
| LogP |
1.115
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
629
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
S1C([H])([H])C(C([H])([H])[H])=C(C(=O)O[H])N2C([C@]([H])([C@@]12[H])N([H])C([C@@]([H])(C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])[H])=O)=O.O([H])[H]
|
| InChi Key |
NBFNMSULHIODTC-CYJZLJNKSA-N
|
| InChi Code |
InChI=1S/C16H17N3O5S.H2O/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);1H2/t10-,11-,15-;/m1./s1
|
| Chemical Name |
(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
|
| Synonyms |
Duricef Cefadroxil monohydrate Cefadroxil
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~13.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6219 mL | 13.1096 mL | 26.2192 mL | |
| 5 mM | 0.5244 mL | 2.6219 mL | 5.2438 mL | |
| 10 mM | 0.2622 mL | 1.3110 mL | 2.6219 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02479867 | COMPLETED | Drug: Cefadroxil | Healthy | Genuine Research Center, Egypt | 2014-03 | Phase 1 |
| NCT03802552 | COMPLETED | Drug: Cefadroxil Drug: Cephalexin |
Osteomyelitis Pyomyositis Septic Arthritis |
University of Colorado, Denver | 2019-05-01 | Phase 1 |
| NCT00834275 | COMPLETEDWITH RESULTS | Drug: Cefadroxil 500 mg Capsules Drug: DURICEF® capsules 500 mg |
Healthy | Teva Pharmaceuticals USA | 2004-09 | Phase 1 |
| NCT02446496 | COMPLETEDWITH RESULTS | Drug: Cefadroxil tablets manufactured by GSK
Drug: Cefadroxil tablets manufactured by NP |
Infections, Urinary Tract | GlaxoSmithKline | 2014-03-31 | Phase 4 |
| NCT02140281 | COMPLETED | Drug: Treatment A (cefadroxil alone) Drug: Treatment B - AZD1722 followed by cefadroxil |
Healthy Volunteers | Ardelyx | 2014-05 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
